Literature DB >> 29331749

Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.

Gwénaëlle Duhil de Bénazé1, Hélène Pacquement1, Cécile Faure-Conter2, Catherine Patte3, Daniel Orbach1, Nadège Corradini2, Claire Berger4, Hélène Sudour-Bonnange5, Cécile Vérité6, Hélène Martelli7, Brice Fresneau8.   

Abstract

METHODS: French patients (≤18years) treated for dysgerminoma between 1985 and 2005 in TGM-85, 90, 95 protocols were included. Treatment was based on primary unilateral oophorectomy followed by prophylactic lymph node irradiation (1985-1998) or a wait-and-see strategy (1998-2005) for localised completely resected tumours (pS1) or by platinum-based chemotherapy for advanced diseases.
RESULTS: Forty-eight patients (median age 12.8 years) were included. Six patients had gonadal dysgenesis. Two had bilateral dysgerminoma. Twenty-eight patients had loco-regional dissemination, seven with para-aortic lymph nodes. None had distant metastases. Primary surgery was performed in 47/48 patients. Among the 15 patients with pS1 tumour: seven did not receive adjuvant treatment, six had lymph node irradiation and two received chemotherapy. Among the 32 patients with advanced tumour, 31 received cisplatinum-based (n = 25) or carboplatin-based (n = 8) regimen with lymph node irradiation for one of them and one did not receive adjuvant treatment. With a median follow-up of 14 years, all patients are alive in complete remission. Five events occurred: 2 contralateral dysgerminomas, 1 peritoneal relapse and 2 second neoplasms (teratoma and melanoma). Bilateral oophorectomy was necessary for 12 patients. Desire of pregnancy was expressed for 17/36 patients with unilateral oophorectomy, which succeeded in 13 cases (5 medically assisted). 2/17 had ovarian failure. The renal function was normal in 24/25 evaluated patients treated with platinum, ifosfamide or irradiation. The hearing function was evaluated on 17/36 patients treated with platinum: 12 Brock grade-0, 3 brock grade-1 and 2 grade-4.
CONCLUSION: Dysgerminoma has an excellent prognosis even in advanced cases with conservative surgery and platinum-based chemotherapy. However the disease and/or treatment resulted in a high rate of bilateral oophorectomies and a significant impact on future fertility.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Children; Clinical study; Dysgerminoma; Late effects; Ovarian tumours

Mesh:

Substances:

Year:  2018        PMID: 29331749     DOI: 10.1016/j.ejca.2017.11.030

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Development of a Data Model and Data Commons for Germ Cell Tumors.

Authors:  Bo Ci; Donghan M Yang; Mark Krailo; Caihong Xia; Bo Yao; Danni Luo; Qinbo Zhou; Guanghua Xiao; Lin Xu; Stephen X Skapek; Matthew M Murray; James F Amatruda; Lindsay Klosterkemper; Furqan Shaikh; Cecile Faure-Conter; Brice Fresneau; Samuel L Volchenboum; Sara Stoneham; Luiz Fernando Lopes; James Nicholson; A Lindsay Frazier; Yang Xie
Journal:  JCO Clin Cancer Inform       Date:  2020-06

2.  Epidemiological profile and clinico-pathological features of pediatric gynecological cancers at Moi Teaching & Referral Hospital, Kenya.

Authors:  Anisa W Mburu; Peter M Itsura; Elkanah O Orang'o; Philliph K Tonui; Elly B Odongo; Afrin F Shaffi; Hellen N Muliro; Thomas N Achia; Allan L Covens; Barry P Rosen
Journal:  Gynecol Oncol Rep       Date:  2022-03-10

Review 3.  Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.

Authors:  Asaf Maoz; Koji Matsuo; Marcia A Ciccone; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson
Journal:  Cancers (Basel)       Date:  2020-05-29       Impact factor: 6.639

4.  Late Recurrence in Ovarian Dysgerminoma Presenting as a Primary Retroperitoneal Tumor: A Case Report and Review of the Literature.

Authors:  Yuichiro Sato; Tohru Hayashi; Hidetaka Yamamoto; Ichiro Niina; Naoya Kuroki; Takeshi Iwamura; Junji Onishi
Journal:  Case Rep Pathol       Date:  2020-02-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.